Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events.

The American journal of medicine - 1 Oct 2010

Rubenfire Melvyn, Brook Robert D, Rosenson Robert S

Abstract excerpt

Statins reduce cardiovascular events and cardiovascular and total mortality in persons at risk for and with coronary disease, but there remains a significant residual event rate, particularly in those with the atherogenic lipid phenotype that is characterized by a low high-density lipoprotein (HDL) cholesterol and increase in non-HDL cholesterol. Large outcome trials designed to assess the value of combining...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atherosclerosis
Share to Cholesterol, LDL
Share to Fatty Acids, Omega-3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hyperlipidemia, Familial Combined

Share to Lipid Metabolism

Share to Niacin

Share to Risk Reduction Behavior

Source

Identifiers

PMID: 20920687
DOI: 10.1016/j.amjmed.2010.03.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events.PMID 20920687Read ↗

[Can cardiovascular events be prevented by raising HDL cholesterol?].Semantic proximity Read ↗

Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis.Semantic proximity Read ↗

The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.Semantic proximity Read ↗

A risk factor for atherosclerosis: triglyceride-rich lipoproteins.Semantic proximity Read ↗

Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP.Semantic proximity Read ↗

The High-Density Lipoprotein Puzzle: Why Classic Epidemiology, Genetic Epidemiology, and Clinical Trials Conflict?Semantic proximity Read ↗

Emerging views of statin pleiotropy and cholesterol loweringSemantic proximity Read ↗

Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.Semantic proximity Read ↗

Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary.Semantic proximity Read ↗

Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.Semantic proximity Read ↗

Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protectionSemantic proximity Read ↗

Clinical implications for statin pleiotropySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.